aSecondary endpoint: Rate of clinically significant exacerbations was reduced from 4.25 12 months prior to mepolizumab exposure (n=821) to 1.11 in the 24 months post-exposure (n=820); rate ratio 0.26 (95% CI: 0.24, 0.29); p<0.001.3
bSecondary endpoint: Median maintenance OCS dose reduced from 10.0 mg/day at baseline (n=298) to 0.0 mg/day at 2 years (n=168). The primary endpoint of exacerbation reduction was met. Median maintenance daily OCS dose reduced from 10.0 mg/day (range: 15.0-5.0mg/day) at baseline to 0.0 mg/day at 2 years (range: 5.0-0.0mg/day).3
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441
© 2020 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.
November 2022 | PM-GB-MPL-WCNT-200026 (V4.0)